Mar. 28 at 2:48 PM
$SCPS Duet's immuno-oncology platform looks promising. STAT3 inhibition could be a game-changer for hard-to-treat tumors. Watching closely as they pivot to DUET-101 for systemic delivery. High risk but potential breakthrough in cancer treatment. a closer look at current performance: https://beyondspx.com/article/scopus-biopharma-inc-scps-navigating-the-challenges-of-biotech-innovation